Breast Cancer Models

Breast cancer remains a leading cause of cancer-related morbidity and mortality worldwide, necessitating comprehensive models to understand its epidemiology, subtypes, and treatment responses. Epidemiologically, breast cancer exhibits significant variation across different populations, with incidence and prevalence influenced by genetic, environmental, and lifestyle factors. The disease manifests in diverse subtypes, notably estrogen receptor-positive (ER + ), human epidermal growth factor receptor 2-positive (HER 2+ ), and triple-negative breast cancer (TNBC), each characterized by distinct molecular profiles and clinical behaviors. To elucidate the complexities of breast cancer, researchers employ a multifaceted approach encompassing in vitro , in vivo , and in silico models. In vitro models, including established cell lines and patient-derived organoids, offer insights into cellular mechanisms and drug responses. These models are instrumental in high-throughput screening and mechanistic studies. In vivo models, such as xenografts and genetically engineered mouse models, replicate human breast cancer within a physiological context, providing a platform for studying tumor microenvironment interactions and therapeutic efficacy. In silico modeling of cancer integrates biological literature with computer-based simulations to investigate hypotheses in a computational environment and complements traditional research methods, enhancing efficiency and effectiveness. It reduces research costs through computational approaches to simulate breast cancer progression and predict treatment responses. These models integrate vast datasets from genomic, transcriptomic, and clinical studies, offering a systems-level perspective and aiding in the identification of potential therapeutic targets. Together, these diverse modeling approaches are critical for advancing our understanding of breast cancer biology and improving clinical outcomes through the development of personalized therapies.